USSTOCK.TODAY
Pre-Market
Log in Sign up

Replimune Group Launches TUDRIQEV and Announces Fiscal Q2 2027 Results

The Motley Fool +1 · ·by G4L

REPL
REPL Replimune Group Inc
$23.28 +4.58%
View chart & analysis →
  1. 1Replimune Group reported that TUDRIQEV is available for commercial use following FDA approval.
  2. 2Replimune recorded a net loss of $57.1 million for the quarter.
  3. 3Replimune held $307.8 million in cash and cash equivalents at the end of the quarter.

So what's the key point?

Replimune Group can now sell its approved medicine in the market. The company had a loss of $57.1 million this quarter but still has $307.8 million in cash.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

Replimune Group Faces Focus on Pipeline Clarity Ahead of September Quarterly Results Earnings Whispers +2 · Oct 23SpaceX retail investors turn net sellers for the first time since the IPO Reuters +9 · Aug 10Capricor Therapeutics Shares Plunge 40% on Release of FDA Briefing Documents InvestorsHub +2 · Jul 28
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news